Mitoxantrone-Induced Extravasation

Nancy Jo Bush

ONF 2005, 32(1), 27-29. DOI: 10.1188/05.ONF.27-29

Jump to a section


    Alley, E., Green, R., & Schuchter, L. (2002). Cutaneous toxicities of cancer therapy. Current Opinion in Oncology, 14, 212-216.

    Brown, K.A., Esper, P., Kelleher, L.O., O'Neil, J.E.B., Polovich, M., & White, J.M. (2001). Chemotherapy and biotherapy: Guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society.

    Camp-Sorrell, D. (1998). Developing extravasation protocols and monitoring outcomes. Journal of Intravenous Nursing, 21, 232-239.

    Dorsett, D.S. (2000). Quality of care. In C. H. Yarbo, M.H. Frogge, M. Goodman, & S. L. Groenwald (Eds.), Cancer nursing: Principles and practice (5th ed., pp. 1581-1608). Sudbury, MA: Jones and Bartlett.

    Gonsette, R.E. (2003). Mitoxantrone in progressive multiple sclerosis: When and how to treat? Journal of the Neurological Sciences, 206, 203-208.

    Goodman, M., & Peterson, J. (1997). Tips for administering chemotherapy. In R.A. Gates & R.M. Fink (Eds.), Oncology nursing secrets (pp. 45-55). Philadelphia: Hanley and Belfus.

    Hadaway, L.C. (2002). I.V. infiltration: Not just a peripheral problem. Nursing, 32(8), 36-42.

    Harris, P.A., & Moss, A.L. (2002). Management of extravasation injuries. ANZ Journal of Surgery, 72, 684.

    Hartung, H.P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrisey, S.P., et al. (2002). Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 360, 2018-2025.

    Immunex. (2002). Novantrone [Package insert]. Thousand Oaks, CA: Author.

    Langstein, H.N., Duman, H., Seelig, D., Butler, C.E., & Evans, G.R. (2002). Retrospective study of the management of chemotherapeutic extravasation injury. Annals of Plastic Surgery, 49, 369-374.

    Skokal, W.A. (2001). Drug disasters: Extravasation. RN, 64(9), 56-62.